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Abstract
Background: To report the predictive value of nail-fold capillaroscopy (NFC) patterns of vasculopathy for systemic
sclerosis (Scleroderma; SSc) in an unselected cohort of patients with Raynaud’s phenomenon (RP).
Methods: Patients referred to a tertiary SSc clinic with RP were evaluated by light/video-NFC. Clinical diagnosis,
details and serology were recorded. Primary RP was defined as RP with no features of connective tissue disease
(CTD)/antibody. NFC patterns were determined: normal, non-specific, ‘early’, ‘active’ or ‘late’ SSc patterns. Fulfilment
of the VEDOSS or 2013 ACR/EULAR criteria for SSc was determined following NFC assessment.
Results: Three hundred forty-seven patients were referred: mean (SD) age 47 (15.2) years. On clinical review, 54
(16 %) did not have RP, 69 (20 %) had primary RP, 52 (15 %) had SSc and 172 (50 %) had secondary RP. NFC SSc
pattern was detected in 80 (23 %) patients; 37/52 with SSc, 30/172 with secondary RP, 9/69 with primary RP and
4/54 with no RP. For identifying patients who met either the VEDOSS or 2013 ACR/EULAR criteria for SSc, detection
of a SSc NFC pattern had a sensitivity of 71 %, specificity 95 %, positive predictive value 84 % and negative
predictive value 90 %.
Conclusions: The absence of SSc NFC pattern in patients with RP or suspected CTD is very valuable in the
exclusion of SSc.
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Background
Nail-fold capillaroscopy (NFC) is a non-invasive method
of evaluating the microcirculation in vivo, developed and
utilised to characterise disease since the early 20th cen-
tury [1, 2]. Primary RP (pRP) is associated with normal
architecture whereas abnormalities are recognised in as-
sociation with secondary RP. The most well described
abnormalities in NFC have been in patients with sys-
temic sclerosis (SSc), with the recognition of the SSc
NFC pattern; presence of early, active or late vasculopa-
thy [3]. The SSc NFC pattern correlates with SSc disease
duration [3], severity [4], and is predictive of future
organ damage [5].
NFC has been shown to be helpful in the assessment
of pRP and predicting progression to connective tissue
disease (CTD) [6–8]; a meta-analysis reported any ab-
normal capillaroscopy pattern offered a positive predict-
ive value of 47 % and negative predictive value of 93 %
for developing CTD [9]. In patients with pRP, a SSc NFC
pattern, in particular, was reported by Pavlov-Dolijanovic
et al, to offer a negative predictive value of 99 % for the
future development of SSc, with an odd ratio of 163
(95 % confidence interval: 97.9, 271.5) [10].
However, although recognised to occur, few studies
have reported the prevalence of a SSc NFC pattern in
the context of an unselected cohort with secondary RP
(sRP) [11–14]. The largest study of 447 patients reported
a SSc NFC pattern in 65 % of 102 SSc patients, 13 % of
186 patients with RP (primary and secondary combined
together), 14 % with undifferentiated CTD (UCTD),
27 % with dermato-/poly-myositis and 8.5 % with Sys-
temic Lupus Erythematosus (SLE) [13]. Due to this lack
of data, the predictive value of a SSc NFC pattern for
the development of SSc in patients presenting with sRP
is unknown.
In 2013, the American College of Rheumatology
(ACR)/European League Against Rheumatism (EULAR)
classification criteria for SSc were developed in an effort
to overcome the relatively low sensitivity of the existing
SSc criteria, particularly in early disease and limited cu-
taneous SSc [15]. Assigning varying weights to specific
features of disease, including fingertip lesions, telangi-
ectasia, abnormal NFC and SSc-related autoantibodies,
sensitivity and specificity was improved to 91 % and
92 % respectively. In addition, the VEDOSS (Very Early
Diagnosis of Systemic Sclerosis) diagnostic criteria for
early SSc were produced, with an aim to detect those at
the early stages of the disease not yet meeting the ACR/
EULAR criteria [16]. In these criteria, the presence of
RP along with anti-nuclear antibody (ANA) and SSc
NFC pattern are major criteria. Therefore, given that a
SSc NFC pattern contributes to meeting both these new
criteria the potential lack of specificity for SSc warrants
further exploration.
Our objective was to describe, in real-life clinical prac-
tice, the association of a SSc NFC pattern with clinical
diagnosis in an unselected cohort of patients with RP at-
tending a tertiary centre NFC service. We also wished to
determine the predictive value of a SSc NFC pattern for
meeting either the 2013 ACR/EULAR or VEDOSS cri-
teria for SSc.
Methods
Patients with RP are referred to our specialist SSc ter-
tiary centre for NFC to aid in the diagnosis, prognosis
and management of RP. Patients with RP that were re-
ferred for NFC between January 2009 and October 2013
formed the basis for this study. The cohort is unselected
and includes both pRP and sRP.
At the time of NFC, clinical diagnosis, RP history and
serological status were used to define patients were de-
fined as having: (i) pRP - RP with no features of CTD/
antibody positivity (ii) sRP - a clinical diagnosis of non-
SSc CTD, such as systemic lupus erythematosus (SLE)
or undifferentiated CTD (UCTD); but also included
patients with features suspicious of (but not fulfilling
formal diagnosis of ) SSc [such as the presence of anti-
nuclear antibody (ANA) or another ‘red flag’ feature,
namely gastro-eosophageal reflux disease (GORD),
digital ulceration, telangiectasia, or puffy fingers)] (iii)
SSc (clinical diagnosis).
Patients were acclimatised to room temperature for at
least 10 min before NFC examination. A small drop of
immersion oil was placed on the nail beds of the eight
fingers (excluding thumbs) and the nail-fold capillaries
were examined by either light microscopy or with the
availability of newer technology, video-microscopy. The
examination was carried out by a physician with a spe-
cialist interest in SSc. NFC patterns were determined as:
normal, non-specific, or ‘early’, ‘active’ or ‘late’ SSc pattern
as described by Cutolo previously [3].
Findings were systematically recorded. A retrospective
analysis of the clinical records determined the fulfilment
of the VEDOSS criteria for early SSc or 2013 ACR/
EULAR criteria for SSc for all patients following NFC
assessment.
A descriptive analysis was carried out using SPSS (version
21, IBM, NY, USA) statistical package.
Results
Patient characteristics
Three hundred forty-seven patients were referred to the
NFC service between January 2009 and October 2013;
mean (SD) age was 47 (15.2) years, 83 % were female.
Table 1 describes the patient characteristics. On clinical
review, 54 (16 %) were determined not to have true RP,
69 (20 %) had pRP, 172 (50 %) had sRP, and 52 (15 %)
had a clinical diagnosis of SSc. Of the patients with SSc,
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29 (56 %) were anti-centromere antibody (ACA) positive,
4 (8 %) anti-topoisomerase antibody (Scl-70) positive; 35
(67 %) had limited cutaneous SSc (lcSSc), 9 (10 %)
dcSSc, 6 (11.5 %) undefined and 6 (11.5 %) overlap; at
referral, 46 (89 %) patients met either VEDOSS criteria
or 2013 ACR/EULAR criteria for SSc. Of those with sRP,
71 (41 %) were being managed for CTD or inflammatory
arthritis whilst 101 (59 %) had either presence of an anti-
body and/or a red-flag feature for SSc.
NFC findings
A SSc NFC pattern was detected in 80 (23 %) patients:
43 with ‘early’, 31 with ‘active’ and six with ‘late’ pattern
of vasculopathy (see Table 2). A SSc NFC pattern was
seen in 37 (71 %) patients with SSc, 30 (17 %) with sRP,
9 (13 %) with pRP and 4 (7 %) with no RP. Considering
only those with non-SSc CTD or inflammatory arthritis;
16 (23 %) of the 71 patients had a SSc NFC pattern; two
of five patients with systemic lupus erythematosis, 8 of
42 patients with undifferentiated CTD, four of six pa-
tients with mixed CTD, one of three patients with Sjog-
ren’s syndrome and 1 of 14 patients with inflammatory
arthritis.
SSc classification criteria
Following NFC, 49/52 (94 %) patients with SSc and 45/
295 (15.3 %) of those without a clinical diagnosis of
scleroderma met the VEDOSS or 2013 ACR/EULAR cri-
teria respectively. In particular, 39 (23 %) patients with
sRP, including 20 (28 %) patients with CTD or inflam-
matory arthritis, met either criteria following NFC.
Considering the entire unselected cohort, the detec-
tion of a SSc NFC pattern had a sensitivity of 71 %
(95 % confidence interval (CI) 61 to 80 %), specificity of
95 % (95 % CI 91 to 97 %), positive predictive value of
84 % (95 % CI 74 to 91 %) and negative predictive value
of 90 % (95 % CI 86 to 93 %) for identifying patients
who met the VEDOSS or 2013 ACR/EULAR criteria.
Discussion
To our knowledge this is the first study to demonstrate
that the absence of any SSc NFC pattern maintains its
known negative predictive value, including in patients
with sRP thought to be at increased risk of SSc. As the
absence of a SSc NFC pattern is extremely valuable in
the exclusion of SSc, NFC could be performed to pro-
vide reassurance to the rheumatologist in the assessment
of both pRP or sRP.
In line with previous studies, we have demonstrated
that the SSc NFC pattern can also be seen in the context
of other CTDs. Our study however, and that of Nagy et
al [13], are the only two to our knowledge that report
NFC findings in an unselected cohort of patients with
RP in large numbers; with the remaining studies involv-
ing less than 67 patients [11, 12, 14]. As a consequence
of these findings, we found some of our patients with
non-SSc CTD now met the new SSc classification criteria.
It is possible these new criteria may lead to an increase in
the prevalence of overlap syndromes.
Table 1 Patient characteristics
Variable No RP Primary RP Secondary RP [subset with antibody
or red flag feature]
SSc All patients
Number, n (%) 54 (15.6) 69 (19.9) 172 (49.6)
[101 (29.1)]
52 (15.0) 347 (100)
Age, years, mean (SD) 42.2 (14.6) 40.6 (13.9) 47.4 (14.0)
[45.3 (14.8)]
58.8 (14.4) 47 (15.2)
Female 47 (87) 51 (74) 145 (84)
[86 (85)]
45 (87) 288 (83)
Duration of RP, months, median (IQR) - 61.0 (24.0, 149.0)
(n = 64)
57 (18.0, 160.0)
[60 (24.0, 180.0)]
(n = 154 [94])
70.0 (30.0, 240.0)
(n = 47)
60.0 (24.0, 166.0)
(n = 265)
Current smokers, n (%) 9/41 (22) 17/57 (30) 40/146 (27)
[22/87 (25)]
7/42 (17) 73/286(26)
Ab positive, n (%) 33 (61) 0 (0) 145 (84)
[91 (90)]
48 (92) 226 (65)
ANA positive, n (%) 32 (59) 0 (0) 142 (83)
[88 (87)]
48 (92) 222 (64)
ACA positive, n (%) 4 (7) 0 (0) 20 (12)
[12 (12)]
29 (56) 53 (15)
Scl-70 positive, n (%) 3 (6) 0 (0) 7 (4)
[3 (3)]
4 (8) 14 (4)
Ab antibody, ACA anti-centromere antibody, ANA antinuclear antibody, IQR inter-quartile range, N number, RP Raynaud’s Phenomenon, Scl-70 anti-topoisomerase
antibody, SD standard deviation, SSc Systemic Sclerosis
Bissell et al. BMC Musculoskeletal Disorders  (2016) 17:342 Page 3 of 5
Interestingly we found that patients meeting the 2013
ACR/EULAR criteria were more likely to have a SSc
NFC pattern than those meeting the VEDOSS criteria
(84 % vs 42 % respectively). This may be related to the
earlier stage of disease in those meeting VEDOSS with
less time for detectable vasculopathic changes at the
nail fold to develop. These findings are important as
the earlier detection and management of SSc may lead
to reduced morbidity and earlier detection of its
complications.
We acknowledge several limitations with this study.
Firstly, we took a pragmatic approach to the NFC exam-
ination with no formal measurements taken to deter-
mine enlarged/mega capillaries. However, the aim of the
study was to capture real-life NFC practice with there-
fore broader application to the general rheumatologist.
Secondly, two different methods of NFC were used,
which might have introduced bias. However, as the clin-
ical diagnosis at referral did not influence the method of
NFC we feel no selection bias occurred. In addition, dif-
ferent NFC methods are employed by the practising
rheumatologists, which we reflect in this report. Also,
mirroring standard clinical practice, the NFC examiners
were not blinded to the clinical diagnosis, possibly
introducing investigator bias. Finally, we acknowledge a
retrospective analysis is at risk of missing important
data, particularly presence of telangiectasia, however, we
would anticipate this study highlights the needs for larger,
more defined prospective studies of a heterogeneous
group of RP patients.
Conclusions
To conclude, although a SSc NFC pattern can be found
in CTDs other than SSc, we have demonstrated a high
specificity for meeting the 2013 ACR/EULAR and VEDOSS
criteria for SSc. More importantly, the high negative
predictive value of the absence of any SSc NFC pattern
in patients with either pRP or sRP is of very high clinical
value in the exclusion of SSc.
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Table 2 NFC patterns seen across diagnoses
No RP (n = 54) Primary RP (n = 69) Secondary RP (n = 172) [subset
with red flag features (n = 101)]
SSc (n = 52) All patients (n = 347)
NFC findings Normal 29 (54) 27 (39) 80 (47)
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7 (14) 143 (41)
Non-specific 21 (39) 33 (48) 62 (36)
[36 (36)]
8 (15) 124 (36)
Early vasculopathy 4 (7) 9 (13) 17 (10)
[10 (10)]
13 (25) 43 (12)
Active vasculopathy 0 (0) 0 (0) 11 (6)
[3 (3)]
20 (39) 31 (9)
Late vasculopathy 0 (0) 0 (0) 2 (1)
[1 (1)]
4 (8) 6 (2)
Any SSc pattern
(early/active/late)
4 (7) 9 (13) 30 (17)
[14 (14)]
37 (71) 80 (23)
Criteria met post NFC VEDOSS 5 (9) 0 (0) 36 (21)
[16 (16)]
12 (23) 53 (15)
2013 ACR/EULAR 1 (2) 0 (0) 3 (2)
[3 (3)]
37 (71) 41 (12)
Either SSc criteria 6 (11) 0(0) 39 (23)
[19 (19)]
49 (94) 94 (27)
ACR American College of Rheumatology, EULAR European League Against Rheumatism, NFC Nail-fold capillaroscopy, RP Raynaud’s Phenomenon, SSc Systemic
Sclerosis, VEDOSS Very early diagnosis of Systemic Sclerosis
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